Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
M&A
MedTech
Qiagen 'open for discussion' on shareholder value
Qiagen’s outgoing chief executive told investors the company does not “comment on rumors” as takeover talks swirl around the diagnostics specialist.
Ben Adams
Feb 6, 2026 9:15am
Medtronic steps up with CathWorks buyout
Feb 4, 2026 9:15am
4 trends driving biopharma M&A this year, per Bain
Jan 28, 2026 5:00pm
Fierce Pharma
Halozyme catches M&A wave to snap up Surf Bio
Jan 28, 2026 2:06pm
With 200 JPM meetings, Novo BD head seeks out the next Metsera
Jan 27, 2026 5:25pm
British biotechs mull going public after yearslong IPO drought
Jan 26, 2026 1:01am